Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 10:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Announces TDP-43 Condensate Modulator Development Candidate for Treatment of ALS and Related Neurodegenerative Diseases

First-in-class condensate-modulating small molecule Development Candidate targeting pathogenic TDP-43 condensates in ALS, FTD and traumatic brain injury.
January 08, 2026 07:00 ET | Source: Aronora

Aronora Appoints Industry Leaders to Drive Next Phase of Growth

Grace E. Colón, Ph.D., Appointed Chair of the Board of Directors John Glasspool Appointed Board Director Lekhan Shivashankar Appointed Chief of Staff New Additions Strengthen Aronora as it Advances...
January 06, 2026 11:30 ET | Source: A Race Against Blindness

A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)

GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr. Stephen Johnston and Kristina Johnston, today announced $1.1 million...
January 05, 2026 14:00 ET | Source: iQor US Inc.

iQor CXBPO™ Acquires OP360 to Expand Global CX Capabilities

iQor CXBPO™ acquires OP360, expanding global CX capabilities and scale while uniting people-first cultures and tech-enabled service excellence.
January 05, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
January 05, 2026 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Announces Key Leadership Appointments

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
December 18, 2025 10:03 ET | Source: Inbenta

Inbenta AI Appoints Channel Veteran Brandon Pineda to Spearhead Aggressive Ecosystem Expansion as Head of Global Partnerships Amid Surging Demand for Production-Ready Enterprise AI

Inbenta AI, an innovator in production-ready AI agents, today announced it has tapped channel veteran Brandon Pineda as its new Head of Global Partnerships
December 17, 2025 07:30 ET | Source: Compass Therapeutics

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics,...
December 11, 2025 07:30 ET | Source: Autobahn Labs

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

Autobahn Labs and Astellas form a strategic partnership to source and develop early-stage drug discovery programs from academia.
December 09, 2025 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science

ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...